Thymic carcinoma surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Marjan Khan (talk | contribs) No edit summary |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Thymic carcinoma}} | {{Thymic carcinoma}} | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{Marjan}} | ||
==Overview== | ==Overview== | ||
Surgery is the mainstay of treatment for thymic carcinoma.<ref name=age>National Cancer Institute. General Information About Thymoma and Thymic Carcinoma Treatment. http://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq. Accessed on 22nd December, 2015.</ref> | |||
==Surgery== | ==Surgery== | ||
Treatment options for thymic carcinoma include the following: | Treatment options for thymic carcinoma include the following:<ref name=age>National Cancer Institute. General Information About Thymoma and Thymic Carcinoma Treatment. http://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq. Accessed on 22nd December, 2015.</ref> | ||
*Surgery | *Surgery | ||
*Radiation | *Radiation | ||
*Cisplatin-based chemotherapy | *Cisplatin-based chemotherapy | ||
For patients with clinically resectable disease, surgical resection is often the initial therapeutic intervention. For clinically borderline or frankly unresectable lesions, neoadjuvant (preoperative) chemotherapy or thoracic radiation therapy, or both, is given. | *For patients with clinically resectable disease, surgical resection is often the initial therapeutic intervention. | ||
*For clinically borderline or frankly unresectable lesions, neoadjuvant (preoperative) chemotherapy or thoracic radiation therapy, or both, is given. | |||
*Patients presenting with locally advanced disease should be carefully evaluated and undergo multimodality therapy. | |||
*Patients with poor performance status and high associated operative risks are generally not considered for these types of aggressive treatments. | |||
*Patients with metastatic disease may respond to combination chemotherapy. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Hematology]] | |||
[[Category:Immunology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 18:36, 10 September 2019
|
Thymic Carcinoma Microchapters |
|
Diagnosis |
|---|
|
Case Studies |
|
Thymic carcinoma surgery On the Web |
|
American Roentgen Ray Society Images of Thymic carcinoma surgery |
|
Risk calculators and risk factors for Thymic carcinoma surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]
Overview
Surgery is the mainstay of treatment for thymic carcinoma.[1]
Surgery
Treatment options for thymic carcinoma include the following:[1]
- Surgery
- Radiation
- Cisplatin-based chemotherapy
- For patients with clinically resectable disease, surgical resection is often the initial therapeutic intervention.
- For clinically borderline or frankly unresectable lesions, neoadjuvant (preoperative) chemotherapy or thoracic radiation therapy, or both, is given.
- Patients presenting with locally advanced disease should be carefully evaluated and undergo multimodality therapy.
- Patients with poor performance status and high associated operative risks are generally not considered for these types of aggressive treatments.
- Patients with metastatic disease may respond to combination chemotherapy.
References
- ↑ 1.0 1.1 National Cancer Institute. General Information About Thymoma and Thymic Carcinoma Treatment. http://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq. Accessed on 22nd December, 2015.